关键信息
-
基因名
Coagulation Factor VII/F7
- 应用
-
别名
FVII; SPCA; proconvertin; Cothromboplastin; Serum Prothrombin Conversation Accelerator; Stable Factor; Eptacog alfa
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P70375
-
表达区间
Ala315~Asp433
-
分子量
16kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Coagulation Factor VII (FVII) is a crucial protein in the blood coagulation cascade, playing a pivotal role in hemostasis by initiating the extrinsic pathway of coagulation. Deficiency or dysfunction of FVII is linked to bleeding disorders, necessitating novel therapeutic approaches. Recombinant FVII (rFVIIa) has emerged as a vital therapeutic agent, particularly for patients with FVII deficiency, hemophilia, and those experiencing uncontrolled bleeding, such as in surgical settings or trauma. The production of rFVIIa through recombinant DNA technology has enabled a consistent and purified source, addressing issues related to transmission of infectious diseases associated with plasma-derived products. Current research focuses on optimizing the production processes to enhance yield and activity, exploring its potential in the treatment of bleeding complications beyond inherited disorders, and understanding its mechanisms at the molecular level to improve efficacy and safety. Investigations into the pharmacokinetics, dose-response relationships, and potential adverse effects are ongoing to refine treatment protocols. Additionally, the development of new formulations aims to extend the therapeutic window of rFVII, making it a more versatile option for diverse clinical applications. The continued exploration of FVII and its recombinant forms is crucial for advancing treatments for coagulation disorders, ultimately aimed at improving patient outcomes and quality of life.
